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rug addiction is a chronic, relapsing disorder in which
 
compulsive drug-seeking and drug-taking behavior persists despite serious
negative consequences. Addictive substances induce pleasant states (euphoria
in the initiation phase) or relieve distress. Continued use induces adaptive changes in
the central nervous system that lead to tolerance, physical dependence, sensitization,
craving, and relapse (Table 1). The addictive drugs discussed here are opioids, cannab-
inoids, ethanol, cocaine, amphetamines, and nicotine.
The World Health Organization
 
1
 
 and the American Psychiatric Association
 
2
 
 use the
term “substance dependence” rather than “drug addiction.” “Drug addiction,” however,
emphasizes the behavioral connotation of the term and is less likely to be confused
with physical dependence.
 
3
 
 We use both terms interchangeably in this review. The Amer-
ican Psychiatric Association’s definition of substance dependence
 
2
 
 requires a patient to
meet at least three of the seven criteria listed in Table 1. Tolerance and physical depend-
ence reflect physiological adaptation to the effects of a drug, whereas the remaining cri-
teria define uncontrollable drug consumption. However, tolerance and physical depend-
ence are neither necessary nor sufficient for a diagnosis of substance dependence.
Substance abuse
 
2
 
 or harmful use,
 
1
 
 a less severe disorder, may result in dependence.
Theories of addiction have mainly been developed from neurobiologic evidence and
data from studies of learning behavior and memory mechanisms. They overlap in some
aspects and are not mutually exclusive. None of them alone can explain all aspects of ad-
diction. It is not our purpose to present a detailed assessment of these theories, especial-
ly because of the complexity of the problem. Generally, addictive drugs can act as posi-
tive reinforcers (producing euphoria) or as negative reinforcers (alleviating symptoms
of withdrawal or dysphoria). Environmental stimuli (cues) associated with drug use it-
self can also induce a conditioned response (withdrawal or craving) in the absence of
the drug.
 
4,5
 
Koob and Le Moal
 
6,7
 
 have proposed that the organism tries to counteract the effects
of a given drug through a vicious circle in which the hedonic set point (the point at which
pleasure is achieved) continually changes in response to the administration of the sub-
stance. They argue that drug addiction results from dysregulation of the reward mecha-
nism and subsequent allostasis, the ability to achieve stability through change. Robinson
and Berridge
 
8,9
 
 emphasize the dissociation between the incentive value of the drug
(“wanting”) and its pleasurable or hedonic effects (“liking”), so that the brain system
involved in the reward mechanism becomes hypersensitized to both the direct effects of
the drug and associated stimuli that are not directly attributable to the drug. This hyper-
sensitization causes pathologic wanting, or craving, independently of the presence of
withdrawal symptoms and leads to compulsive drug-seeking and drug-taking behavior.
Although liking progressively decreases, drugs become pathologically wanted (craving).
Complementary to this incentive–sensitization theory,
 
8,9
 
 compulsive drug-seeking and
drug-taking behavior is facilitated by difficulties in decision making and the ability to
judge the consequences of one’s own actions. These cognitive difficulties have been
linked to deficits in the activation of areas in the prefrontal cortex.
 
10,11
 
 An overlap in
d
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 4, 2017. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
349;10
 
www.nejm.org september 
 
4
 
, 
 
2003
 
The
 
 new england journal 
 
of
 
 medicine
 
976
 
memory mechanisms and the mechanisms of drug
addiction has also been proposed.
 
12
 
pharmacologic and physicochemical 
properties of drugs
 
Pharmacologic and physicochemical properties of
drugs are important factors in how drugs are con-
sumed. Liposolubility increases the passage of a
drug through the blood–brain barrier, water solu-
bility facilitates the injection of a drug, volatility fa-
vors the inhalation of drugs in vapor form, and heat
resistance favors smoking of the drug.
 
13
 
 Character-
istics such as rapid onset and intensity of effect in-
crease the potential for abuse
 
14,15
 
; therefore, sub-
stances that rapidly reach high levels in the brain are
usually preferred (e.g., flunitrazepam is preferred
over triazolam, and smoking “crack” cocaine is
preferred to intranasal administration).
 
16,17
 
 A short
half-life (e.g., that of heroin) produces more abrupt
and intense syndromes of withdrawal than does a
long half-life (e.g., that of methadone).
 
13
 
personality and psychiatric disorders
 
Personality traits and mental disorders are major
conditioning factors in drug addiction. Risk-taking
or novelty-seeking traits favor the use of addictive
drugs.
 
18
 
 Polydrug use is frequent among those
with drug addiction, and many fulfill the criteria
for dependence on or abuse of (or both) more than
one substance.
 
19
 
 Psychiatric disorders, particularly
schizophrenia, bipolar disorder, depression, and at-
tention-deficit–hyperactivity disorder, are associat-
ed with an increased risk of abuse. A dual diagnosis
(substance abuse and mental disorder) has unfavor-
able implications for management and outcome.
 
20
 
genetic factors
 
Genetic factors that influence the metabolism and
the effects of drugs contribute to the risk of addic-
tion.
 
21
 
 Men whose parents were alcoholics have an
increased likelihood of alcoholism even when they
were adopted at birth and raised by parents who
were not alcoholic, and they also have a reduced sen-
sitivity to alcohol that predicts the development of
alcoholism.
 
22
 
 Carriers of an allele of aldehyde dehy-
drogenase that encodes an isoenzyme with reduced
activity are less likely to abuse alcohol owing to the
presence of increased levels of acetaldehyde, which
is responsible for aversive effects.
 
23
 
 A Leu7Pro poly-
morphism of the neuropeptide Y gene has been cor-
related with increased alcohol consumption,
 
24
 
 and
single-nucleotide polymorphisms of the gene en-
coding the µ opioid receptor correlates with an in-
creased likelihood of heroin abuse.
 
25
 
 A deficiency
in the cytochrome P-450 2D6 gene blocks the enzy-
matic conversion of codeine to morphine, thereby
preventing codeine abuse.
 
26
 
 
With regard to nicotine dependence, subjects
with defective cytochrome P-450 2A6 *2 and *4
alleles, which impair the metabolism of nicotine,
factors influencing drug
abuse and dependence
 
Table 1. Definitions of Terms Used in Drug Addiction.
Craving
 
 (formerly called 
 
psychological dependence
 
) is an intense desire to re-
experience the effects of a psychoactive substance. Craving is the cause of 
relapse after long periods of abstinence.
 
Physical or physiological dependence
 
 is an outdated term that refers to physi-
cal tolerance and the withdrawal syndrome.
 
Priming 
 
refers to a new exposure to a formerly abused substance. This expo-
sure can precipitate rapid resumption of abuse at previous levels or at 
higher levels.
 
Relapse
 
 is a resumption of drug-seeking or drug-taking behavior after a period 
of abstinence. Priming, environmental cues (people, places, or things as-
sociated with past drug use), and stress can trigger intense craving and 
cause a relapse.
 
Reward
 
 is a stimulus that the brain interprets as intrinsically positive or as 
something to be attained.
 
Sensitization
 
 is the increase in the expected effect of a drug after repeated ad-
ministration (e.g., increased locomotor activation after the administration 
of psychostimulants). Sensitization also refers to persistent hypersensitiv-
ity to the effect of a drug in a person with a history of exposure to that drug 
(or to stress). Sensitization is one of the neurobiologic mechanisms in-
volved in craving and relapse.
 
Substance abuse
 
 is characterized by recurrent and clinically significant ad-
verse consequences related to the repeated use of substances, such as fail-
ing to fulfill major role obligations, use of drugs in situations in which it is 
physically hazardous, occurrence of substance-related legal problems, and 
continued drug use despite the presence of persistent or recurrent social 
or interpersonal problems.
 
Substance dependence
 
 is a cluster of cognitive, behavioral, and physiological 
symptoms indicating that a person is continuing to use a substance de-
spite having clinically significant substance-related problems. For sub-
stance dependence to be diagnosed, at least three of the following must be 
present: symptoms of tolerance; symptoms of withdrawal; the use of a 
substance in larger amounts or for longer periods than intended; persist-
ent desire or unsuccessful attempts to reduce or control use; the spending 
of considerable time in efforts to obtain the substance; a reduction in im-
portant social, occupational, or recreational activities because of drug use; 
and continued use of a substance despite attendant health, social, or eco-
nomic problems.
 
Withdrawal syndrome
 
 is a constellation of signs and symptoms that follows 
the abrupt discontinuation or reduction in the use of a substance or after 
blockage of the actions of a substance with antagonists (e.g., naloxone in 
heroin addiction). The syndrome can also be produced by cues associated 
with substance use (
 
conditioned withdrawal
 
). Symptoms tend to be the 
opposite of those produced after short-term exposure to a drug. With-
drawal is one of the causes of compulsive drug-taking behavior and short-
term relapse.
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smoke fewer cigarettes and are less likely to be de-
pendent than subjects who are homozygous for
these alleles.
 
27
 
 A single-nucleotide polymorphism
in the gene encoding fatty acid amide hydrolase, a
major endocannabinoid-inactivating enzyme, has
recently been associated with both an increased like-
lihood of recreational use of illegal drugs and prob-
lem use of drugs or alcohol.
 
28
 
 The minor (A1) allele
of the 
 
Taq
 
IA D2 dopamine receptor gene has been
linked to severe alcoholism; polysubstance, psycho-
stimulant abuse or dependence; and opioid and nic-
otine dependence.
 
29
 
 Advances in genomic scanning
(for quantitative trait loci) will allow the identifica-
tion of allelic variants that contribute to the vulner-
ability to addiction.
 
30
 
opioids
 
Short-term administration of heroin or morphine
produces euphoria, sedation, and a feeling of tran-
quility. Repeated administration rapidly produces
tolerance and intense physical dependence. Over-
dose can cause lethal respiratory depression. Nu-
merous reports have documented impairments in
health related to long-term heroin use.
 
31,32
 
Opioids activate specific receptors (µ, 
 
d
 
, and 
 
k
 
)
that couple the G protein (Fig. 1 and 2). Knockout
mice lacking the µ receptor neither exhibit the be-
havioral effects induced by opioids nor become
physically dependent when given opioids (Table 2).
The µ receptor has also been implicated in mediat-
ing or modulating the rewarding effect of other
drugs of abuse (e.g., cannabinoids). Mice in which
different receptors (CB
 
1
 
 cannabinoid and D2 dopa-
mine receptors) and transporters (dopamine) have
been knocked out have been used to demonstrate
the effect of systems other than the opioid on opi-
oid-induced pharmacologic responses.
 
33
 
cannabinoids
 
The use of marijuana or hashish produces feelings
of relaxation and well-being and impairs cognitive
function and performance of psychomotor tasks.
Overdose can induce panic attack and psychosis.
 
34
 
A high incidence of cannabis consumption has been
reported among patients with schizophrenia.
 
35
 
Symptoms of withdrawal — restlessness, irritabil-
ity, and insomnia — are subtle and appear in heavy
consumers.
 
36
 
 The long-term effects of high doses
of cannabinoids is a complex and controversial
subject. Although there is evidence that long-term
use of cannabis impairs memory,
 
37,38
 
 the cause of
the marijuana amotivational syndrome — loss of
energy and drive to work — remains unclear.
 
34
 
G-protein–coupled cannabinoid CB
 
1
 
 receptors
(Fig. 1 and 2), which are richly distributed in basal
ganglia and cerebral-cortex regions, are implicated
in cannabinoid abuse and addiction. In contrast to
other neurotransmitters, endocannabinoids act as
retrograde messengers at many central synapses.
They are released from postsynaptic neurons and
activate CB
 
1
 
 receptors on presynaptic neurons, in-
hibiting the release of neurotransmitters.
 
39
 
 Natural
ligands of CB
 
1
 
 receptors (anandamide, 2-arachido-
nylglycerol, and noladin ether) have a shorter period
of action than synthetic or plant-derived cannab-
inoids.
 
39
 
 Selective synthetic agonists and antago-
nists of CB
 
1
 
 receptors are currently being developed
for medical purposes.
 
40,41
 
ethanol
 
When ethanol is given at low doses or initially dur-
ing acute ethanol intoxication, it is perceived as a
stimulant owing to the suppression of central in-
hibitory systems, but as the plasma levels of ethanol
increase, sedation, motor incoordination, ataxia,
and impaired psychomotor performance appear.
 
42
 
The withdrawal syndrome (seizures and delirium
tremens) may be severe and clinically challenging.
The long-term effects of ethanol consumption have
been extensively reviewed elsewhere.
 
43,44
 
Ethanol modifies the activity of serotonin
(5-hydroxytryptamine
 
3
 
 [5-HT
 
3
 
]) receptors, nicotin-
ic receptors, 
 
g
 
-aminobutyric acid type A (GABA
 
A
 
)
receptors, and the 
 
N
 
-methyl-
 
d
 
-aspartate (NMDA)
subtype of glutamate receptors. Ethanol acutely in-
hibits binding to the 
 
d
 
-opioid receptor, and long-
term exposure to ethanol increases the density of
µ and 
 
d
 
 receptors.
 
45
 
 Its actions on nearly all recep-
tors are the result of a direct interaction with the re-
ceptor protein.
 
46
 
cocaine and amphetamines
 
Short-term administration of psychostimulants
such as amphetamine produces euphoria, a feeling
of well-being, and alertness as well as increased
arousal, concentration, and motor activity. These
substances increase blood pressure and the pulse
rate and induce the release of corticotropin-releas-
ing factor, corticotropin, and cortisol.
 
47-49
 
 Long-
term use may cause irritability, aggressive and ster-
eotyped behavior, and paranoid-like psychosis.
drug effects and
mechanisms of action
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Whereas signs of withdrawal can be mild (depres-
sion, lack of energy, and insomnia), craving is very
intense.
 
50
 
 So-called designer derivatives of am-
phetamine (3,4-methylenedioxymethamphetamine
[MDMA], or “ecstasy”) produce euphoria
 
51,52
 
 and
increased empathy (an “entactogenic” effect), but
some derivatives have hallucinogenic effects. Acute
intoxication with a psychostimulant can cause cer-
ebral hemorrhage, hyperthermia and heat stroke,
the serotonin syndrome, panic, and psychosis. The
serotonin syndrome is characterized by altered
mental status, autonomic instability, and neuro-
muscular abnormalities resulting in hyperthermia.
So-called designer derivatives of amphetamine may
have toxic effects on dopamine and serotonin neu-
rons.
 
53,54
 
Cocaine is a potent blocker of the dopamine-,
norepinephrine-, and serotonin-uptake transport-
ers. Amphetamines have a more complex mecha-
nism of action. Amphetamines cause neuronal
storage vesicles in the cytoplasm to release neuro-
transmitters to the synapse; inhibit the uptake of
dopamine, norepinephrine, and serotonin by mem-
brane transporters; and act as mild inhibitors of
monoamine oxidase (Fig. 2). Amphetamine and
methamphetamine seem to be more selective for
dopamine and norepinephrine than for serotonin
transporters, but MDMA and designer amphet-
amines are more selective for the serotonin trans-
porter.
 
55
 
other addictive substances
 
Nicotine binds to neuronal nicotinic acetylcholine
receptors,
 
56
 
 and barbiturates and benzodiazepines
bind and modulate the ion-channel–gated GABA
 
A
 
receptors (Fig. 1 and 2).
 
57
 
 The psychotomimetic
actions of dissociative anesthesics (phencyclidine
and ketamine) are mediated by their noncompeti-
tive antagonism at the NMDA-sensitive glutamate
receptor (ligand-gated ion channel).
 
58
 
 Lysergide or
mescaline (classic hallucinogens) are partial ago-
nists at 5-HT
 
2a
 
 receptors,
 
58
 
 whereas salvinorin A in-
duces their effects through the activation of 
 
k
 
-opi-
oid receptors.
 
59
 
animal models
 
Various animal behavioral paradigms have been
used to study the neuronal substrates involved in ad-
diction, especially euphoria and rewarding effects,
including self-stimulation, self-administration, and
conditioned place-preference models (Fig. 3).
 
60
 
 In
the place-preference model, the rewarding proper-
ties of a compound are associated with the particular
characteristics of a given environment (place); after
conditioning, the animal prefers to spend more time
in the environment associated with the drug. Mo-
lecular studies have identified regulatory processes
that occur after drug administration at the level of
receptors, membrane transporters, and their asso-
ciated signaling proteins. Useful strains of mice
have been developed by genetically disrupting drug
targets (receptors and transporters) or proteins in
the pathways of these targets. Genetic alterations
are generally present throughout development in
these mice. Therefore, when the phenotypes of in-
terest are absent, the effect of a drug could actually
reflect compensatory changes in other neurobiolog-
ic systems.
 
33,61
 
 To avoid this limitation, conditioned
and tissue-specific knockout animals have been de-
veloped.
 
62
 
For some drugs, the risk of abuse in humans can
neurobiology
 
Figure 1. Ionotropic Mechanisms of Action of Drugs of Abuse.
 
Drugs of abuse are usually receptor agonists, such as endogenous neuro-
transmitters, that act on two different types of membrane receptors: ionotro-
pic (shown in this figure) and metabotropic (shown in Fig. 2). Ionotropic 
receptors (ligand-gated ion channels) mediate fast synaptic transmission. 
The neurotransmitter or the drug binds to the receptor, which undergoes a 
conformational change, opening the gate and allowing ions to enter the cyto-
plasm and causing depolarization or polarization of the membrane and acti-
vation of various proteins. Nicotine binds to nicotinic cholinergic receptors, 
which contain a sodium channel. Benzodiazepines, barbiturates, and ethanol 
bind to 
 
g
 
-aminobutyric acid (GABA) type A receptors, facilitating the entry of 
chloride. Ethanol and phencyclidine inhibit 
 
N
 
-methyl-
 
d
 
-aspartate–sensitive 
glutamate receptors, which contain calcium and sodium channels. Phencycli-
dine also acts as an antagonist.
Extracellular
Channel
Gate
Intracellular
Ca2+, Na+, K+, Cl¡
Drugs of abuse
Nicotine, benzodiazepines,
barbiturates, ethanol, phencyclidine
Neurotransmitters
Acetylcholine, g-aminobutyric 
acid, glutamate, serotonin
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on April 4, 2017. For personal use only. No other uses without permission. 
 Copyright © 2003 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
349;10
 
www.nejm.org september 
 
4, 2003
 
mechanisms of disease
 
979
 
be predicted with the use of tests based on behavior-
al paradigms in animals. These methods, however,
are not systematically used during the development
of centrally acting drugs,
 
63
 
 probably because the
methods are not required by regulatory agencies.
 
neuroanatomical substrates
 
The neuronal pathways of drug addiction are com-
ponents of the mesocorticolimbic dopamine sys-
tems that originate in neurons in the ventral teg-
mental area (Fig. 4).
 
64
 
 All drugs of abuse act on this
 
Figure 2. Metabotropic Mechanisms of Action of Drugs of Abuse.
 
Metabotropic (G-protein–coupled) receptors mediate slow synaptic transmission. G proteins are trimeric structures 
composed of two functional units: an 
 
a
 
 subunit that catalyzes GTPase activity (converting guanosine triphosphate [GTP] 
to guanosine diphosphate [GDP]), and a 
 
b
 
–
 
g
 
 dimer that interacts with the 
 
a
 
 subunit when bound to GDP (inactive 
state). The binding of the agonist activates a nearby G protein. The 
 
a
 
 subunit bound to GTP subsequently dissociates 
from its 
 
b
 
 and 
 
g
 
 subunits. Both can activate or inhibit enzymes (adenylyl cyclase or phospholipase C) that synthesize 
second messengers such as cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate, inositol tri-
phosphate, and diacylglycerol. In addition, the 
 
b
 
 and 
 
g
 
 subunits directly regulate calcium-, sodium-, and potassium-ion 
channels. Second messengers also regulate ion channels by activating protein kinases, which phosphorylate (P) such 
channels. Protein kinases induce pharmacologic effects and produce changes in transcription factors such as cAMP-
responsive element–binding protein (CREB) and 
 
∆
 
FosB. Opioids bind to opioid receptors (which reduce cAMP levels), 
and cannabinoids bind to cannabinoid receptors. Classic hallucinogens are partial agonists of serotonin receptors. Am-
phetamines and cocaine have an indirect action on receptors, increasing the synaptic levels of dopamine, norepineph-
rine, and serotonin (facilitating release and inhibiting reuptake, respectively). These neurotransmitters activate different 
subtypes of dopaminergic, adrenergic, and serotonergic receptors.
Drugs of abuse
Opioids, cannabinoids,
hallucinogens, phencyclidine
Receptor
Second-messenger–
generating enzyme
GDP



GTP
 

Gate
Ion channel
Neurotransmitters
Endogenous opioids, endogenous cannabinoids,
dopamine, norepinephrine, serotonin
Drugs of abuse
Amphetamines, cocaine
P
Protein kinase
Transcription factors
(CREB, FosB)
Second
messenger
Pharmacologic
effects
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system at different levels. The mesolimbic circuit
includes projections from cell bodies of the ventral
tegmental area to limbic structures, such as the
nucleus accumbens, amygdala, and hippocampus.
This circuit has been implicated in acute reinforcing
effects, memory, and conditioned responses linked
to craving and the emotional and motivational
changes of the withdrawal syndrome. The mesocor-
tical dopamine circuit includes projections from the
ventral tegmental area to the prefrontal cortex, orb-
itofrontal cortex, and anterior cingulate. It is in-
volved in the conscious experience of the effects of
drugs, drug craving, and the compulsion to take
drugs. The mesolimbic and the mesocortical dopa-
mine circuits operate in parallel and interact with
each other and with other areas — forming the so-
called extended amygdala — by means of projec-
tions from the GABA neurons of the nucleus accum-
bens to the ventral tegmental area and prefrontal
cortex and glutamatergic projections from the pre-
frontal cortex to the nucleus accumbens and ventral
tegmental area.11,12,64
the leading role of the dopamine pathway
Both natural rewards (food, drink, and sex) and ad-
dictive drugs stimulate the release of dopamine
from neurons of the presynaptic ventral tegmental
area into the nucleus accumbens, causing eupho-
ria and reinforcement of the behavior. In the case
of natural rewards, there is a very rapid adaptive
change, or habituation, after a few experiences, and
the novelty or unexpectedness of the reward seems
to play a major part in the initial response. The re-
sponse to addictive drugs is not influenced by ha-
bituation, and each dose of the drug stimulates the
release of dopamine.65 Moreover, dopamine medi-
ates the hedonic consequences of a reinforcing stim-
ulus, promoting associative learning about the stim-
ulus or anticipating its rewarding effects.65 During
the withdrawal syndrome associated with opioids,
cannabinoids, ethanol, psychostimulants, and nic-
otine, there is a substantial decrease in dopamine
levels in the nucleus accumbens.66
Dopamine binds to a G-protein–coupled recep-
tor with two main subtypes, D1-like receptors (D1
and D5) and D2-like receptors (D2, D3, and D4).
D1-like receptors activate adenylyl cyclase, whereas
D2-like receptors inhibit the enzyme (Fig. 1 and 2).
A membrane dopamine transporter moves the re-
leased neurotransmitter from the extracellular space
back into the presynaptic neuron (uptake). Animals
can be taught to self-administer D1-like and D2-like
receptor agonists.55,67
Dopamine and Opioids
Opioids release dopamine mainly by an indirect
mechanism that decreases the activity of GABA-
inhibitory interneurons in the ventral tegmental
area. Rodents can be taught to self-administer
µ-receptor agonists into both the ventral tegmental
area and the nucleus accumbens. Stimulation of
k receptors decreases dopamine levels in the nucle-
us accumbens and produces aversive responses. Ro-
dents will continue to self-administer opioid into
the nucleus accumbens even in the presence of do-
paminergic lesions or after a dopamine antagonist
has been given. Reward and physical dependence on
opioids are mediated by the activation of µ receptors
(Table 2), since reinforcement is blocked by selec-
tive receptor antagonists. Mice in which the µ recep-
tor has been knocked out do not exhibit place pref-
erence or withdrawal signs after the administration
of morphine.68
Dopamine and Cannabinoids
∆9-Tetrahydrocannabinol and other cannabinoids
increase the efflux of dopamine in the nucleus ac-
cumbens and cell firing in the ventral tegmental
area by their actions on CB1 receptors in glutamater-
gic and GABA-ergic neurons associated with the
nucleus accumbens and ventral tegmental area.69
Laboratory animals cannot be taught to self-admin-
ister ∆9-tetrahydrocannabinol, and spontaneous
symptoms of withdrawal do not appear after such
drugs are stopped. Highly potent, short-acting syn-
thetic cannabinoid agonists (e.g., Win 55,212-2) in-
duce self-administration behavior in rodents.70 Se-
lective cannabinoid antagonists (e.g., SR 141716A)
precipitate a withdrawal syndrome in cannabinoid-
dependent animals, but at doses that are difficult
* The model is defined in Figure 3. 
Table 2. Inactivation of Opioid Receptors in Knockout Mice.
Opioid
Receptor That
Is Knocked Out
Withdrawal
Syndrome
 Self-
Administration
Model*
Place-
Preference
Model* Analgesia
µ Receptor No No No No
d Receptor Yes Unknown Unknown Yes
k Receptor Yes (reduction
in symptoms)
Unknown Yes Yes
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to extrapolate to the consumption of plant-derived
cannabis in humans.71
Dopamine and Ethanol
Ethanol raises dopamine levels in the nucleus ac-
cumbens by an indirect mechanism: it increases the
firing of dopamine neurons in the ventral tegmental
area by activating GABAA receptors or by inhibiting
NMDA receptors. Alcohol administration induces
specific, long-lasting adaptive changes in the com-
position of NMDA receptor subunits, which en-
hances the function of NMDA receptors. These find-
ings are the basis of the experimental and clinical
use of NMDA antagonists for treating the ethanol-
withdrawal syndrome and reducing alcohol intake
and relapse rate.43,72 Opioid and serotonin recep-
tors seem to have a role in the reinforcing effects of
ethanol. In rats, naltrexone decreases the rate of self-
administration of ethanol, and selected 5-HT3 an-
tagonists block the release of dopamine induced by
ethanol and reduce alcohol consumption.45,72
Dopamine and Cocaine and Amphetamines
Cocaine and amphetamines increase synaptic do-
pamine levels by inhibiting the activity of dopamine
transporters. Imaging of the brain has shown that
cocaine and amphetamines increase extracellular
dopamine levels in the striatum and that euphoria
is related to the occupancy of dopamine transporters
by cocaine and amphetamines.73 Lesions in dopa-
mine pathways, inhibition of dopamine synthesis,
and dopamine antagonists markedly attenuate the
rate of self-administration of cocaine in rats. Dopa-
mine-transporter–knockout mice are insensitive to
the locomotor stimulatory effects and are less sen-
sitive than normal mice to the behavioral effects of
psychostimulants, but they will still self-administer
cocaine and amphetamine. This effect may indicate
a contribution of the serotonin and norepinephrine
systems to the maintenance of the rewarding prop-
erties of cocaine.55,61
Dopamine and Nicotine
Nicotine exerts its positive reinforcing effects by act-
ing on a4b2 nicotinic acetylcholine receptors locat-
ed on the somatodendritic membranes of the dopa-
mine cells of the ventral tegmental area and possibly
by sensitizing a7 nicotinic acetylcholine receptors
located on glutamate terminals. Experiments with
mutant mice lacking b2 nicotinic acetylcholine re-
ceptors confirm the primary role of this receptor in
promoting the self-administration of nicotine.74,75
Figure 3. Animal Behavioral Paradigms Used to Study Positive Reinforcing 
(Rewarding) Actions of Drugs.
In Panel A, animals are trained to press a lever to obtain a drug or saline (self-
administration) or to receive intracranial current in brain-rewarding loci (self-
stimulation). In Panel B, mice are placed in a box with two discrete chambers, 
or environments, and are then repeatedly injected with a drug in one environ-
ment and with saline in the other environment. In a drug-free state, the animal 
is allowed access to both environments, and the amount of time spent in each 
environment is recorded. A positively reinforcing effect of the drug is apparent 
if the mouse spends more time in the environment in which the drug was ad-
ministered (place preference) than in the one in which saline was administered.
Lever
Electric
stimulator
Pump dispensing 
drug or saline
A
B
Computer
Drug
Saline
?
Drug-tested mouse prefers chamber
in which drug was given
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the opioid pathway
The opioid system is another pathway in the brain
involved in the rewarding effects of addictive
drugs.71 The importance of this system in addiction
to cannabinoids was brought out by studies in which
opioid-receptor antagonists were found to attenuate
the self-administration of cannabinoids and precip-
itate behavioral signs of withdrawal in rats treated
with cannabinoid agonists for long periods.76 Opi-
oid antagonists reduce the consumption and self-
administration of ethanol in animals, but naltrexone
does not reduce the rate of relapse or alcohol con-
sumption in patients with alcoholism.77 By con-
trast, µ-receptor–knockout mice cannot be induced
to self-administer alcohol.72 The opioid system also
inhibits the self-administration of nicotine in ani-
mals. Indeed, naloxone precipitates withdrawal in
rats that receive nicotine for long periods and re-
duces cigarette consumption in smokers.74 In addi-
tion, nicotine-induced conditioned place preference
is abolished in µ-receptor–knockout mice.78
tolerance and withdrawal
Tolerance leads to modifications of drug use to ob-
tain desired effects, by increasing the dose, reducing
the intervals between doses, or both. Withdrawal
compels addicts to resume drug use to prevent or
reduce physical symptoms and dysphoria. Both tol-
erance and withdrawal increase compulsive drug-
seeking and drug-taking behavior and are essential
in maintaining the addiction. Sensitization, howev-
er, is also important. Molecular adaptations related
to tolerance and dependence have been studied ex-
tensively in animal models of opioid and cocaine ad-
diction, and the results can be extrapolated to other
substances.12,79,80
Opioid Tolerance
Short-term administration of opioid activates the
µ-opioid Gai/o-coupled receptor, which inhibits
long-term drug use
and neuroadaptation
Figure 4. Neural Reward Circuits Important in the Reinforcing Effects of Drugs of Abuse.
As shown in the rat brain, mesocorticolimbic dopamine (DA) systems originating in the ventral tegmental area include 
projections from cell bodies of the ventral tegmental area to the nucleus accumbens, amygdala, and prefrontal cortex; 
glutamatergic (GLU) projections from the prefrontal cortex to the nucleus accumbens and the ventral tegmental area; 
and projections from the g-aminobutyric acid (GABA) neurons of the nucleus accumbens to the prefrontal cortex. Opi-
oid interneurons modulate the GABA-inhibitory action on the ventral tegmental area and influence the firing of norepi-
nephrine (NE) neurons in the locus ceruleus. Serotonergic (5-HT) projections from the raphe nucleus extend to the 
ventral tegmental area and the nucleus accumbens. The figure shows the proposed sites of action of the various drugs 
of abuse in these circuits.
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adenylyl cyclase, lowers cyclic adenosine mono-
phosphate (cAMP) levels, decreases cAMP-depend-
ent protein kinase A activity, and reduces phos-
phorylation of cytoplasmic and nuclear targets,
including cAMP–responsive element–binding pro-
tein (CREB), a transcription factor. Activation of
µ receptors can also cause the phosphorylation of
some mitogen-activated protein kinases, which in
turn phosphorylate CREB and other transcription
factors.12,79,81,82 Decreases in the number of opioid
receptors have been related in some reports to the
development of opioid tolerance. Continuous stim-
ulation desensitizes opioid receptors, which be-
come phosphorylated by G-protein–coupled recep-
tor kinases; b-arrestins then bind to the receptors,
causing them to be internalized by the neuron.83
Other studies, however, have found that opioids that
cause internalization of the opioid receptors are in-
efficient in initiating tolerance.84
Opioid Withdrawal
Chronic activation of opioid receptors produces ef-
fects opposite to those of acute activation. It up-
regulates cAMP signaling pathways by increasing
the activity of adenylyl cyclases (subtypes I and VII),
cAMP-dependent protein kinase A, and tyrosine
hydroxylase. In addition, chronic activation of opi-
oid receptors increases the phosphorylation of
CREB and ∆FosB, factors regulating gene transcrip-
tion.66,79,85 These changes correlate with the man-
ifestations of the withdrawal syndrome.
Up-regulation of cAMP is a homeostatic re-
sponse to the inhibition of the locus ceruleus by opi-
oids and a key mechanism in withdrawal. The locus
ceruleus is a noradrenergic nucleus that regulates
arousal, responses to stress, and the activity of the
autonomic nervous system. Tolerance to the inhib-
itory effects of opioids occurs in the locus ceruleus
during long-term administration. When opioid lev-
els fall, the firing rates of neurons in the locus are
unopposed and lead to adrenergic overactivation.
A direct relation between overactivity of the locus
ceruleus neurons and the somatic expression of opi-
oid withdrawal has been demonstrated.86 Mecha-
nisms other than noradrenergic neurons may also
participate in opioid withdrawal because destruc-
tion of the locus ceruleus does not alter naloxone-
precipitated or spontaneous opioid withdrawal.87
In the nucleus accumbens, a similar up-regula-
tion of the cAMP pathway, including activation of
CREB, occurs after long-term administration of opi-
oids, ethanol, or cocaine. CREB increases the pro-
duction of dynorphin, which activates k receptors in
the neurons of the ventral tegmental area and de-
creases the release of dopamine in the nucleus ac-
cumbens. These changes contribute to the negative
emotions (dysphoria and anhedonia) present dur-
ing the early phases of abstinence.66,79
Stress Systems
Drug administration and withdrawal activate central
and peripheral stress systems.88 Short-term admin-
istration elevates peripheral glucocorticoid levels
and central corticotropin-releasing factor levels.
These hormonal elevations have been related to the
rewarding properties of drug use. During withdraw-
al, an increase in corticotropin-releasing factor in
the amygdala has been related to stress and negative
effects of abstinence.47,80
molecular mechanisms of sensitization 
and relapse
Long-term administration of addictive drugs pro-
duces alterations in the brain that increase vulnera-
bility to relapse and facilitate craving even months
or years after successful detoxification. Factors in-
volved in relapse and craving include acute reexpo-
sure to the drug or drug-priming, exposure to envi-
ronmental stimuli previously paired with drug use
or conditioned drug cues, and exposure to environ-
mental stressors (Table 1). The extent of sensitiza-
tion varies with different drugs and is responsible
for responses, craving, and relapse.
Functional Changes
Repeated administration of opioids, psychostimu-
lants, or nicotine sensitizes laboratory animals to the
stimulant or rewarding effects, or both, of these ad-
dictive substances. Behavioral sensitization is asso-
ciated with marked and long-lasting alterations in
the functional activity of the mesocorticolimbic
dopamine system, particularly in glutamate and
dopamine transmission in the nucleus accum-
bens.12,67 Elevated levels of the R1 subunit of
a-amino-3-hydroxy-5-methyl-4-isoxazolepropion-
ic acid (AMPA) subtype of glutamate receptors
seems to be involved in sensitization and relapse.89
Stress or a single dose of addictive substances with
different molecular mechanisms of action (cocaine,
amphetamine, morphine, ethanol, or nicotine) pro-
duces similar degrees of enhancement in the
strength of glutamate excitatory synapses (AMPA-
sensitive glutamate receptors) on dopamine neu-
rons in the ventral tegmental area. The administra-
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tion of a glucocorticoid antagonist blocked the ac-
tions of stress but not those of addictive substances.
These changes can have a role in behavioral sensi-
tization.90
Sensitization is associated with long-lasting
adaptive changes in the patterns of expression of
genes of the terminal mesolimbic dopamine sys-
tems,79 in particular the activation of proteins be-
longing to the family of transcription factor activator
protein 1, such as Fos proteins. In self-administra-
tion models, long-term treatment with morphine,
cocaine, or nicotine increases the expression of the
family of Fos-related transcription factors, particu-
larly the extremely stable isoforms of ∆FosB. The
persistent increase in the expression of Fos genes
in mesolimbic structures is in part a consequence
of the activation of the cAMP cascade through
D1 dopamine receptors in the ventral tegmental
area.85,91,92
Structural Changes
Exposure to addictive drugs can cause long-lasting
structural changes in neurons. Opioids decrease the
size and the caliber of dendrites and soma of dopa-
mine neurons of the ventral tegmental area.93 Re-
peated use of cocaine or amphetamine increases the
number of dendritic branch points and spines on
both medium spiny neurons in the nucleus accum-
bens and pyramidal neurons in the medial prefron-
tal cortex.94 Neurotrophic factors seem to be re-
sponsible for these changes. Modifications in the
density of dendritic spines and neurotrophic factors
have also been implicated in long-term potentiation
and long-term depression by AMPA-sensitive gluta-
mate receptors.
The glutamate system of the brain is responsible
for the long-term plasticity associated with learn-
ing and memory. It is therefore not surprising that
the same glutamatergic mechanisms also underlie
addiction-related behavior.12,66,79,95,96 Behavioral
sensitization can persist for weeks or months and
is augmented by environmental cues (e.g., people,
places, or paraphernalia associated with past drug
use).12 These cues and sensitization contribute to
relapse. Interestingly, the processes involved in sen-
sitization overlap the neuronal substrates and path-
ways involved in the rewarding properties of drug
abuse.7,9
Advances in the neurobiology of drug addiction
have led to the identification of neuronal substrates
responsible for the rewarding effects of prototypical
drugs of abuse, which are crucial to the addictive
process. There is increasing evidence that prolonged
exposure to drugs of abuse produces long-lasting
effects in cognitive and drug-rewarding circuits.
For this reason, addiction should be considered a
chronic medical illness.97,98 Symptoms of with-
drawal can be treated, and maintenance therapy is
available for most drugs of abuse,43,98-101 but the
development of long-term strategies based on med-
ication, psychosocial support, and continued mon-
itoring97,98 is a challenging clinical goal.
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